Editorial Board
Chiara Maria Mazzanti
Pisan Foundation for Science Onlus · Italy
Editorial leadership for Journal of Clinical and Diagnostic Pathology ISSN 2689-5773
Biography
- Tumors apparently identical at the microscopic observation can have entirely different clinical behaviors in terms of survival and response to treatment, on the basis of their specific molecular alterations.
- The modern personalized medicine can arrest the progress of the disease by means of drugs able to target specific pathologically modified proteins.
- The transformation of a population of cells from normal to tumor occurs gradually, through the progressive accumulation of several gene mutations transmitted from a mother cell to daughter cells.
- Some of these modified genes give origin to proteins able to increase the proliferative ability of the cells, whereas others allow tumor cells to invade the near tissues and to colonize distant organs, causing the death of the patient.
- As consequence of a progressive heterogeneity, tumor cells and molecules acquire specific abilities, but, like the different instruments in an orchestra, interplay in a highly regulated dialogue necessary to favor malignancy.
- The genome/transcriptome of the tumor micro-environment, divided in its components, is essential for understanding progression to metastatic disease.
- Understanding this evolution allows to develop new molecular targeted drugs and to optimize the actual therapeutic treatments.
- Chiara Maria Mazzanti’s laboratory is involved in mapping the cellular networks perturbed during cancer progression by systematic, high-throughput, genome-wide analysis at both the DNA and mRNA level
- Chiara Maria Mazzanti received from the University of Pisa her Master’s degree in Biological Sciences and her PhD in Experimental Oncology.
- She spent many years abroad, at the Laboratory of Human Neurogenetics, NIAAA, NIH, Bethesda MD, USA, at the Advanced Technology Center National Cancer Institute of Health (NCI/NIH), and at the Laboratory of Human Cytogenetics, Cancer Research UK London Research Institute, London, UK.
- Recently she got her Specialization in Clinical Pathology at the University of Pisa.
Selected publications
- CXCL12α/SDF‐1 from perisynaptic Schwann cells promotes regeneration of injured motor axon terminals 2017 cited 68×
- Mouse Mammary Tumor Virus (MMTV) and MMTV-like Viruses: An In-depth Look at a Controversial Issue 2022 cited 26×
- Learning and actioning general principles of cancer cell drug sensitivity Recent 2025 cited 23×
- Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives 2023 cited 14×
- Sedoheptulose Kinase SHPK Expression in Glioblastoma: Emerging Role of the Nonoxidative Pentose Phosphate Pathway in Tumor Proliferation 2022 cited 11×
- Identification of New Potential Prognostic and Predictive Markers in High-Grade Osteosarcoma Using Whole Exome Sequencing 2023 cited 10×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JCDP for your work?
This journal is guided by Chiara Maria Mazzanti (Pisan Foundation for Science Onlus) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.